



Original research article

The alterations in alcohol dehydrogenase and aldehyde dehydrogenase activities in the sera of patients with renal cell carcinoma



Karolina Orywal^{a,*}, Wojciech Jelski^a, Tadeusz Werel^b, Maciej Szmítkowski^a

^a Department of Biochemical Diagnostics, Medical University of Białystok, Białystok, Poland

^b Department of Urology, Medical University of Białystok, Białystok, Poland

ARTICLE INFO

Article history:

Received 12 September 2016

Accepted 9 May 2017

Available online 28 July 2017

Keywords:

Alcohol dehydrogenase isoenzymes

Aldehyde dehydrogenase

Renal cell carcinoma

ABSTRACT

Purpose: In a previous study we showed that the total activity of alcohol dehydrogenase (ADH) and its isoenzyme class I was significantly higher in renal cancer (RCC) cells compared to normal kidney. The aim of this study was to compare the activities of ADH isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with different stages of RCC and healthy subjects.

Materials and methods: Serum samples were taken from 54 patients with clear cell RCC (17 patients in stage II, 22 in stage III and 15 in stage IV) and 52 healthy patients. Class III, IV of ADH and the total ADH activity was measured by the photometric method. For the measurement of ADH class I, II and the total ALDH activity we employed the fluorometric method.

Results: The total activity of ADH and its isoenzyme class I were significantly higher in the sera of patients with every stage of RCC compared to healthy subjects. The analysis of ALDH activity did not indicate significant differences between tested groups.

Conclusions: The increased activity of total ADH and its isoenzyme class I in the sera of patients with RCC, seems to be caused by isoenzymes being released from cancerous cells and may be useful for diagnostics of renal cancer.

© 2017 Medical University of Białystok. Published by Elsevier B.V. All rights reserved.

1. Introduction

Renal Cell Carcinoma (RCC) is one of the most common malignancies of the genitourinary tract, accounting for about 3% of all adult cancers [1]. Despite advances in diagnosis, about 20–30% of all patients are diagnosed already with metastatic disease and extremely poor prognosis. Moreover one-third of RCC patients develops distant metastases after resection of the primary tumor [2]. Tumor status has been associated with a number of metabolic and biochemical alterations. The subject of a new studies are certain molecules which could have a meaning in carcinogenesis and tumor progression. Several data have shown a role of tetraspanins, CD 133, calbindin, glutathione S-transferase P, retinal dehydrogenase 1 and aldehyde dehydrogenase in pathogenesis of renal cell carcinoma [3–6].

Studies of Jelski and Szmítkowski show that differences of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) activity between cells of many cancers and healthy tissue may be one of the factors intensifying carcinogenesis [7].

Moreover, changes of ADH and ALDH activity in cancer cells are reflected in serum of patients because of releasing these enzymes from malignant tissue [7]. Human alcohol dehydrogenase and aldehyde dehydrogenase exist in multiple molecular forms that have been grouped into several classes. The best characterized function of these enzymes is a metabolism of ethanol and the other alcohols, also role in protection against products of lipid peroxidation and some exogenous xenobiotics. It was also found that ADH and ALDH take part in biosynthesis of retinoic acid, an important factor for cell differentiation and regeneration [8,9].

In our previous study we showed that normal and cancerous cells of kidney exhibit the activity of alcohol dehydrogenase and aldehyde dehydrogenase. Furthermore, the activity of class I ADH isoenzymes and total ADH were significantly higher in cancer tissue than in unchanged renal cells. Moreover, the activity of ADH seems to be disproportionately high compared to the activity of ALDH, what suggests an increased ability of cancer cells to form the highly toxic and mutagenic acetaldehyde and initiating disorders in metabolism of many biologically important substances [10].

While various markers have been studied in RCC, the clinical significance of alcohol dehydrogenase and aldehyde dehydrogenase has not been elucidated. In this study we investigated the

* Corresponding author at: Department of Biochemical Diagnostics, Medical University of Białystok, Jana Kilińskiego 1, 15-089 Białystok, Poland.
E-mail address: orywalk@umb.edu.pl (K. Orywal).

activity of ADH, its isoenzymes and the total activity of ALDH in the sera of patients with renal cell carcinoma.

2. Material and methods

2.1. Material

Serum samples were taken before surgery from 54 patients (31 men and 23 women; mean age 58 years, range 34–83 years) with clear cell renal cell carcinoma. The mean BMIs (body mass index) of patients were 24.5 kg/m². 18/54 patients were current smokers, 6/54 were ex-smokers and 30/54 were lifelong non-smokers. None of the patients had received chemotherapy or radiotherapy before sample collection, and were diagnosed as stage II (17 patients), III (22 patients) or IV (15 patients) of renal cell cancer. Control group were serum samples taken from 52 healthy subjects (30 men and 22 women; mean age 58 years, range 51–67 years old) with mean BMI 23.6 kg/m². 19/52 were current smokers and 33/52 non-smokers. All of the patients from tested and control group had a history of occasional alcohol consumption.

The research protocol was approved by the Medical University of Białystok's Human Care Committee located in Białystok, Poland (Approval Nr R-I-002/436/2013). All patients from tested and control group gave their informed consent for the examination.

2.2. Methods

2.2.1. Determination of total ADH activity

Total ADH activity was estimated by the photometric method using *p*-nitrosodimethylaniline (NDMA) as a substrate [11]. The reaction mixture (2 mL) contained serum (0.1 mL), 1.8 mL of a 26 μM solution of substrate in 0.1 M of sodium phosphate buffer, pH 8.5 and 0.1 mL of mixture containing 0.25 M *n*-butanol and 5 mM NAD⁺. The reduction of NDMA was monitored at 440 nm on a Shimadzu UV/VIS 1202 spectrophotometer (Shimadzu Europa GmbH, Duisburg, Germany).

2.2.2. Determination of total ALDH activity

Aldehyde dehydrogenase activity was measured using the fluorogenic method based on the oxidation of 6-methoxy-2-naphthaldehyde to fluorescent 6-methoxy-2-naphthoate [12]. The reaction mixture contained 60 μL of serum, 60 μL of substrate, 20 μL of 11.4 mM NAD⁺ and 2.8 mL of 50 mM of sodium phosphate buffer, pH 8.5. The mixture also contained 50 μL of a 12 mM solution of 4-methylpyrazole as a specific inhibitor of ADH activity. The fluorescence was read at an excitation wavelength of 310 and an emission wavelength of 360 nm on a Shimadzu RF-5301 spectrofluorophotometer (Shimadzu Europa GmbH, Duisburg, Germany).

2.2.3. Determination of class I and II ADH isoenzymes

Class I and II ADH isoenzyme activity was measured using fluorogenic substrates (4-methoxy-1-naphthaldehyde for class I and 6-methoxy-2-naphthaldehyde for class II) in a reduction reaction according to Wierzychowski et al. [13]. The assays were performed in a reaction mixture containing a serum (60 μL), substrate (150 μL of 300 μM), NADH (100 μL of 1 mM) and 0.1 M of sodium phosphate buffer, pH 7.6 (2.69 mL) using the conditions previously described [14]. The measurements were performed on a Shimadzu RF-5301 spectrofluorophotometer at an excitation wavelength of 316 nm for both substrates and emission of 370 nm for class I and 360 nm for class II isoenzymes.

2.2.4. Determination of class III ADH isoenzyme

The assay mixture for class III alcohol dehydrogenase contained a serum (100 μL), formaldehyde as a substrate (100 μL of 1 mM),

glutathione (100 μL of 1 mM) and NAD⁺ (240 μL of 1.2 mM) in 0.1 mol NaOH-pyrophosphate buffer pH 8.0 [15]. The final volume was 2 mL. The reduction of NAD⁺ was monitored at 340 nm and 25 °C on a Shimadzu UV/VIS 1202 spectrophotometer.

2.2.5. Determination of class IV ADH isoenzyme

The assay mixture for class IV of ADH activity contained serum (50 μL), *m*-nitrobenzaldehyde as a substrate (132 μL of 80 μM) and NADH (172 μL of 86 μM) in 0.1 M sodium phosphate buffer pH 7.5 [16]. The oxidation of NADH was monitored at 340 nm and 25 °C on a Shimadzu UV/VIS 1202 spectrophotometer.

2.2.6. Statistical analysis

Preliminary statistical analysis (Chi-square test) revealed that the distribution of ADH and ALDH activities did not follow a normal distribution. Consequently, the Wilcoxon test was used for statistical analysis. All data was expressed in mIU/l and presented using median, range and mean values. Statistically significant differences were defined as comparisons resulting in *p* < 0.05.

3. Results

The activities of total ADH, ALDH and ADH isoenzymes in the sera of patients with renal cell carcinoma are presented in Table 1. The total activity of alcohol dehydrogenase was significantly higher (about 26%) in the serum of patients with renal cancer than in healthy subjects. The median total activity of ADH was 1213.0 mIU/l in the RCC group and 895.0 mIU/l in the control group. The analysis of ALDH activity did not indicate significant differences between total tested group and healthy persons.

The comparison of ADH isoenzymes activities showed that the highest difference was exhibited by class I ADH. The median activity of this class of isoenzymes in the cancer group increased by about 24% (1.785 mIU/l) in comparison to the control level (1.338 mIU/l). The increase of ADH I activity was statistically significant. The other tested classes of ADH isoenzymes had higher activities in the serum of patients with cancer but the differences were not statistically significant (*p* > 0.05).

The analysis of particular ADH isoenzymes activities depending on the progression stage of carcinoma, showed the tendency of ADH I activity to increase in accordance with the advance of disease (Fig. 1). Significantly higher ADH class I activity was found in every stage (from II to IV) of cancer compared to the control group. In the stage II of cancer advancement we observed about 20% increase of ADH I activity compared to the control group. In the stage III the increase in class I activity was above 23% and in the IV stage – 26% in comparison to healthy subjects. The activity of total ADH was found to be also significantly higher in patients with renal cancer without dependence on tumor stage. The other isoenzymes did not exhibit any characteristic changes of activity correlating with stage of disease. The total activity of ALDH also did not indicate significant differences between advancement stages.

4. Discussion

The malignant transformation is based on the loss of control mechanisms, disorders in cell differentiation and uninhibited growth. The metabolism of cancer cells is in many ways different than in healthy tissue.

Renal cell carcinoma is characterized by an abnormally high glycogen deposition caused by altered enzyme activities [17]. Many studies reported decreased expression of glucose 6-phosphatase, aminoacylase-I and aldehyde dehydrogenase-1 in RCC [18,19]. ALDH catalyses an oxidation of aldehydes to carboxylic compounds and this reaction is considered as a general detoxification process. Sreerama *et al* revealed that ALDH-1 take part in the

Table 1

The comparison of ADH isoenzymes and ALDH activities in the sera of patients with different stages of renal cell carcinoma.

TESTED GROUP	ADH I Median Range Mean	ADH II Median Range Mean	ADH III Median Range Mean	ADH IV Median Range Mean	ADH Total Median Range Mean	ALDH Total Median Range Mean
Renal cancer (n = 54)	1.785 1.020–2.510	14.620 10.285–18.814	11.412 7.980–14.745	5.583 3.957–7.030	1213.0 824.0–1520.0	2.493 1.709–3.226
Stage II (n = 17)	1.765 1.632 0.844–2.381	14.549 14.590 10.300–18.708	11.362 11.384 8.121–14.470	5.493 5.527 3.923–6.930	1172.0 1202.0 862.0–1468.0	2.467 2.474 1.686–3.120
Stage III (n = 22)	1.613 1.762 1.028–2.464	14.504 14.640 10.278–18.847	11.296 11.422 7.916–14.769	5.426 5.604 3.963–7.057	1165.0 1216.0 823.0–1524.0	2.403 2.505 1.705–3.202
Stage IV (n = 15)	1.746 1.835 1.074–2.567	14.563 14.680 10.279–18.910	11.343 11.426 7.945–14.862	5.510 5.654 3.965–7.171	1174.0 1221.0 815.0–1545.0	2.454 2.517 1.706–3.255
Control group (n = 52)	1.820 1.284 0.754–1.921	14.595 14.510 10.447–18.520	11.404 11.375 7.848–14.223	5.568 5.476 3.936–6.813	1180.0 895.0 579.0–1151.0	2.480 2.426 1.707–3.132
	1.338 $p^a < 0.001$ $p^b < 0.001$ $p^c < 0.001$ $p^d < 0.001$	14.483 $p^a = 0.487$ $p^b = 0.427$ $p^c = 0.383$ $p^d = 0.275$	11.035 $p^a = 0.367$ $p^b = 0.474$ $p^c = 0.352$ $p^d = 0.538$	5.375 $p^a = 0.403$ $p^b = 0.376$ $p^c = 0.287$ $p^d = 0.376$	865.0 $p^a < 0.001$ $p^b < 0.001$ $p^c < 0.001$ $p^d < 0.001$	2.420 $p^a = 0.378$ $p^b = 0.305$ $p^c = 0.397$ $p^d = 0.295$

Data are expressed as mIU/L.


 p^a , cancer vs control group. p^b , stage II vs control group. p^c , stage III vs control group. p^d , stage IV vs control group.

detoxification of chemotherapeutic agents such as cyclophosphamide, so decrease of this enzyme activity can be the reason of disturbances in this process [20].

Aldehyde dehydrogenase has been characterized as a cancer stem cell marker, which plays a key role in various biological processes in tumor, including cell proliferation, invasiveness and chemoresistance. Recent data of *Abourbih et al* reported that ALDH1 expression did not correlate with primary tumor grade, stage or with the clinical outcome but ALDH1 membrane expression was significantly higher in low stage as compared to high stage of RCC tumors. Interesting is also that metastatic tumors expressed significantly lower amounts of ALDH1 than primary tumors [21]. During disease progression and metastasis, tumor cells lose the expression patterns of the normal epithelium from which they originate, and therefore healthy kidney has been shown to express large amounts of ALDH1. This confirm that metastases may form altered pathways than the primary tumors, which would clarify differences in enzymes expression [21].

In our previous study we found that the total activity of aldehyde dehydrogenase in cancer cells of RCC is at the same level as in normal renal tissue [10]. These findings are similar to our results in serum patients with renal cancer. There is no significant difference between ALDH activity in serum cancer patients and healthy controls. We also found that renal cell cancer patients have significantly higher total activity of alcohol dehydrogenase and its class I isoenzyme in the serum. But proteomic analysis conducted by *Sun et al* provide that ADH protein is down regulated in clear cell RCC compared with corresponding normal kidney tissue [6].

One possible explanation for increased ADH activity could be that with disease progression, tumor cells lose the expression patterns of the normal epithelium from which they originate. Moreover differences in ADH and ALDH activity between cancer cells and healthy tissue may be one of the factors intensifying carcinogenesis. Increase in ADH activity with normal ALDH activity suggests that cancer cells have a greater capability for ethanol oxidation and less ability to remove acetaldehyde. Numerous

**Fig. 1.** Comparison of ADH isoenzymes and ALDH activities in the sera of RCC patients.

experiments have shown that acetaldehyde has direct mutagenic and carcinogenic effect because of interferes with DNA synthesis and repair and forms of stable adducts [22].

Many recent data revealed that kidney alcohol dehydrogenase activity increased significantly after ethanol administration what affected the capacity of the kidney to prevent NADH accumulation in the cytosol. The kidney was not able to balance the NADH excess even though an increase in malate dehydrogenase, lactate dehydrogenase, aspartate and alanine transaminase activities was noted [23]. Moreover, after long-term ethanol consumption kidney reduce decreasing glutathione/oxidized glutathione ratio, what indicate oxidative stress [24]. These results showed specific changes in kidney antioxidant system and glutathione status as a consequence of long-term ethanol administration. Chronic ethanol consumption leads to induction of cytochrome P450 2E1 associated with an increased production of reactive oxygen species, which are an important factor in ethanol-related carcinogenesis.

Cancer cells can also release isoenzymes to the serum, what can be helpful in malignant diagnosis. In our data, increase in ADH I activity can origin from the renal cancer cells. These findings are similar to studies of *Jelski et al* in gastrointestinal tract cancers. Liver and colorectum cancer cells exhibits increased activity of ADH I what is the reason of elevated activity of this isoenzyme in the serum of cancer patients. In esophagus and stomach neoplasia, cancer cells have increased activity of ADH IV and patients have elevated ADH IV activity in serum [7].

ADH and ALDH play a significant role in the metabolism of many biologically important substances, including retinoic acid (RA). ADH catalyzes the oxidation of retinol to retinal, which is converted to retinoic acid by ALDH. Enzyme, which especially plays a role in RA synthesis is ADH class I. In situ hybridization showed that class I ADH mRNA was localized in kidney, where significant retinoic acid levels were detected [25]. Retinoic acid is particularly essential because of its profound effects on cellular growth and differentiation. Depletion of systemic and tissue-specific retinoid acid may have consequences for cell proliferation, differentiation and possibly malignant transformation [26]. Disturbances between ADH and ALDH activities in cancer cells of renal cell carcinoma can lead to disorders in RA synthesis what can be a factor entangled in kidney carcinogenesis.

5. Conclusions

In conclusion, we can state that the activity of class I ADH isoenzymes and the total activity of ADH were elevated in the sera of patients with renal cell carcinoma as compared to the healthy control. This activity is probably delivered from renal cancer cells. Significantly increased ADH I activity already in early stage of renal cancer suggest also a potential role of this isoenzyme as a non-specific marker of renal cell carcinoma.

Conflict of interest

The authors declare no conflict of interest.

Financial disclosure

The authors have no funding to disclose.

References

- [1] Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhauser FD, Rao PN, et al. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. *Eur Urol* 2012;61(5):88895, doi:http://dx.doi.org/10.1016/j.eururo.2012.01.012.
- [2] Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. *Cancer* 2008;113(1):78–83, doi:http://dx.doi.org/10.1002/cncr.23518.
- [3] Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. *Nat Rev Cancer* 2009;9(1):40–55, doi:http://dx.doi.org/10.1038/nrc2543.
- [4] Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. *Semin Cancer Biol* 2010;20(2):77–84, doi:http://dx.doi.org/10.1016/j.semcancer.2010.03.004.
- [5] Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. *Mol Cancer Ther* 2010;9(9):2450–7, doi:http://dx.doi.org/10.1158/1535-7163.MCT-10-0530.
- [6] Sun CY, Zang YC, San YX, Sun W, Zhang L. Proteomic analysis of clear cell renal cell carcinoma: identification of potential tumor markers. *Saudi Med J* 2010;31:525–32.
- [7] Jelski W, Szmítkowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. *Clin Chim Acta* 2008;395(1–2):1–5, doi:http://dx.doi.org/10.1016/j.cca.2008.05.001.
- [8] Hellgren M, Strömberg O, Gallego O, Martras S, Farres J, Persson B, et al. Alcohol dehydrogenase 2 is a major hepatic enzyme for human retinol metabolism. *Cell Mol Life Sci* 2007;64:498–505, doi:http://dx.doi.org/10.1007/s00018-007-6449-8.
- [9] Singh S, Arcaroli J, Thompson DC, Messersmith W, Vasiliou V. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. *Adv Exp Med Biol* 2015;815:281–94, doi:http://dx.doi.org/10.1007/978-3-319-09614-8_16.
- [10] Orywal K, Jelski W, Werel T, Szmítkowski M. The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in renal cell carcinoma. *Exp Mol Pathol* 2015;98(3):403–6, doi:http://dx.doi.org/10.1016/j.yexmp.2015.03.012.
- [11] Skursky L, Kovar J, Stachova MA. Sensitive assay for alcohol dehydrogenase activity in blood serum. *Anal Biochem* 1979;89:65–71.
- [12] Wierzychowski J, Wroczynski P, Laszuk K, Interewicz E. Fluorimetric detection of aldehyde dehydrogenase activity in human blood, saliva, and organ biopsies and kinetic differentiation between class I and II isozymes. *Anal Biochem* 1997;245:69–78.
- [13] Wierzychowski J, Dafeldecker W, Holmquist B, Vallee BL. Fluorimetric assay for isozymes of human alcohol dehydrogenase. *Anal Biochem* 1989;178:57–62.
- [14] Jelski W, Mroczko B, Szmítkowski M. The diagnostic value of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. *Dis Dis Sci* 2010;55(10):2953–7, doi:http://dx.doi.org/10.1007/s10620-009-1098-4.
- [15] Koivusalo M, Baumann M, Uotila L. Evidence for the identity of glutathione-dependent formaldehyde dehydrogenase and class III alcohol dehydrogenase. *FEBS Lett* 1989;257:105–9.
- [16] Dohmen K, Baraona E, Ishibashi H, Pozzato G, Moretti M, Matsunaga C, et al. Ethnic differences in gastric α -alcohol dehydrogenase activity and ethanol first metabolism. *Alcoholism Clinical and Experimental Research* 1996;20:1569–76, doi:http://dx.doi.org/10.1111/j.1530-0277.1996.tb01701.x.
- [17] Steinberg P, Storkel S, Oesch F, Thoenes W. Carbohydrate metabolism in human renal clear cell carcinomas. *Lab Invest* 1992;13:506–11.
- [18] Schmoll D, Balabanov S, Schwarck D, Burchell A, Kleist B, Zimmermann U, et al. Differential expression of the subunits of the glucose 6-phosphatase system in the clear cell type of human renal cell carcinoma- no evidence for an overexpression of protein kinase B. *Cancer Lett* 2001;167:85–90.
- [19] Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. *Eur J Biochem* 2001;268:5977–80, doi:http://dx.doi.org/10.1046/j.0014-2956.2001.02546.x.
- [20] Sreerama L, Sladek NE. Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolising enzymes in human breast cancer. *Clin Cancer Res* 1997;3:1901–14.
- [21] Abourbih S, Sircar K, Tanguay S, Kassouf W, Aprikian A, Mansure J, et al. Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study. *World J Surg Oncol* 2013;11:298.
- [22] Millonig G, Wang Y, Homann N, Bernhardt F, Qin H, Mueller S, et al. Ethanol-mediated carcinogenesis in the human esophagus implicates CYP 2E1 induction and the generation of carcinogenic DNA-lesions. *Int J Cancer* 2011;128(3):533–40, doi:http://dx.doi.org/10.1002/ijc.25604.
- [23] Dinu D, Nechifor MT, Movileanu L. Ethanol-induced alterations of the antioxidant defense system in rat kidney. *J Biochem Mol Toxicol* 2005;19:386–95, doi:http://dx.doi.org/10.1002/jbt.20101.
- [24] Nechifor MT, Dinu D. Ethanol-induced redox imbalance in rat kidneys. *J Biochem Mol Toxicol* 2011;25:224–30, doi:http://dx.doi.org/10.1002/jbt.20379.
- [25] Ang HL, Deltour L, Zgombic-Knight M, Wagner MA, Duester G. Expression patterns of class I and class IV alcohol dehydrogenase genes in developing epithelia suggest a role for alcohol dehydrogenase in local retinoic acid synthesis. *Alcohol Clin Exp Res* 1996;20:1050–64.
- [26] Seitz HK, Stickel F. Molecular mechanism of alcohol-mediated carcinogenesis. *Nat Rev Cancer* 2007;7:599–612.